Journal Mobile Options
Table of Contents
Vol. 37, No. 3, 2013
Issue release date: April 2013
Am J Nephrol 2013;37:212-222
(DOI:10.1159/000346948)

Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

de Zeeuw D. · Akizawa T. · Agarwal R. · Audhya P. · Bakris G.L. · Chin M. · Krauth M. · Lambers Heerspink H.J. · Meyer C.J. · McMurray J.J. · Parving H.-H. · Pergola P.E. · Remuzzi G. · Toto R.D. · Vaziri N.D. · Wanner C. · Warnock D.G. · Wittes J. · Chertow G.M.
aDepartment of Clinical Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands; bDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; cDepartment of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Ind., dREATA Pharmaceuticals, Irving, Tex., and eDepartment of Medicine, AHS Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, Ill., USA; fBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; gDepartment of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; hRenal Associates, PA, San Antonio, Tex., USA; iUnit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Bergamo, Italy; jDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Tex., and kDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, Calif., USA; lDivision of Nephrology, Department of Medicine, University of Würzburg, Würzburg, Germany; mDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Ala., nStatistics Collaborative, Inc., Washington, D.C., and oDepartment of Medicine, Stanford University School of Medicine, Palo Alto, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD. Methods: Herein, we describe the design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON) trial, a multinational, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial designed to determine whether long-term administration of bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors) safely reduces renal and cardiac morbidity and mortality. Results: The primary composite endpoint is time-to-first occurrence of either end-stage renal disease or cardiovascular death. Secondary endpoints include the change in eGFR and time to occurrence of cardiovascular events. Conclusion: BEACON will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011.
  2. Heerspink HJ, de Zeeuw D: The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011;8:392-402.
  3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
  4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
  5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
  6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
  7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De FU, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
  8. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
  9. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, et al: Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 2011;58:729-736.
  10. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, et al: Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:131-136.
  11. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
  12. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
  13. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
  14. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
  15. Kelly KJ, Dominguez JH: Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 2010;32:469-475.
  16. Wu CC, Sytwu HK, Lin YF: Cytokines in diabetic nephropathy. Adv Clin Chem 2012;56:55-74.
  17. Luis-Rodriguez D, Martinez-Castelao A, Gorriz JL, De-Alvaro F, Navarro-Gonzalez JF: Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes 2012;3:7-18.

    External Resources

  18. Miyamoto T, Carrero JJ, Stenvinkel P: Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20:662-668.
  19. Anders HJ, Ryu M: Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011;80:915-925.
  20. Pergola P, Krauth M, Huff W, Ferguson D, Ruiz S, Meyer C, et al: Effect of bardoxolone on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011;33:469-476.
  21. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al: Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-336.
  22. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, et al: Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007;18:2749-2757.
  23. US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
  24. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD: Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract 2008;109:c109-c118.
  25. Demoulin N, Beguin C, Labriola L, Jadoul M: Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels. Nephrol Dial Transplant 2011;26:220-226.
  26. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
  27. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, et al: Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:2251-2257.
  28. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, et al: Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010;56:1082-1094.
  29. Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I, et al: Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo Study. Clin Exp Nephrol 2010;14:333-339.
  30. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, et al: Impact of age and overt proteinuria on outcomes of stage 3-5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010;5:1558-1565.
  31. Weldegiorgis MT, Lambers Heerspink HJ, de Zeeuw D, et al: Is ESRD/renal replacement therapy a precise clinical meaningful renal endpoint in drug trials? (Abstract) J Am Soc Nephrol 2012;23 (404A).
  32. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW: New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011;74:537-545.
  33. Heerspink HJ, Holtkamp FA, de Zeeuw D, Ravid M: Monitoring kidney function and albuminuria in patients with diabetes. Diabetes Care 2011;34(suppl 2):S325-S329.
  34. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974-2984.
  35. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
  36. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ: Bardoxolone methyl decreases megalin and activates Nrf2 in the monkey kidney. J Am Soc Nephrol 2012;23:1663-1673.
  37. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. Am J Kidney Dis 2006;48(suppl 1):S1-S322.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50